ADVFN Logo
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

TCRR TCR2 Therapeutics Inc

1.48
0.00 (0.00%)
Last Updated: 20:00:00
Delayed by 15 minutes

Period:

Draw Mode:

Volume 0
Bid Price 1.55
Ask Price 1.38
News -
Day High

Low
1.41

52 Week Range

High
2.04

Day Low
Company Name Stock Ticker Symbol Market Type
TCR2 Therapeutics Inc TCRR NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.00% 1.48 20:00:00
Open Price Low Price High Price Close Price Prev Close
1.48
Trades Volume Avg Volume 52 Week Range
0 0 - 1.41 - 2.04
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 1.48 USD

TCR2 Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 58.11M - - - -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

TCR2 Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No TCRR Message Board. Create One! See More Posts on TCRR Message Board See More Message Board Posts

Historical TCRR Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.000.000.000.0000.000.00%
1 Month0.000.000.000.0000.000.00%
3 Months0.000.000.000.0000.000.00%
6 Months0.000.000.000.0000.000.00%
1 Year1.482.041.411.66354,1290.000.00%
3 Years23.4025.220.8216.17504,533-21.92-93.68%
5 Years17.3035.860.82110.50363,095-15.82-91.45%

TCR2 Therapeutics Description

TCR2 Therapeutics Inc is a clinical-stage cell therapy company. It is engaged in developing a pipeline of novel T cell therapies for cancer patients suffering from solid tumors by powering the T cell receptor (TCR) with its proprietary, first-in-class TCR Fusion Construct T cells (TRuC-T cells). The company's TRuC-T cells specifically recognize and kill cancer cells by harnessing the entire TCR signaling complex, independent of human leukocyte antigens, which is effective in patients with solid tumors.

Your Recent History

Delayed Upgrade Clock